

# Indoco Remedies Receives USFDA EIR for API Manufacturing Facility at Patalganga

Updated on 11 Dec 2025, 05:53 PM  
Reviewed by: Ashish T | ScanX News Team

## Overview

Indoco Remedies has received an Establishment Inspection Report (EIR) from the USFDA for its Active Pharmaceutical Ingredient (API) manufacturing facility in Patalganga. This approval confirms the facility's compliance with USFDA quality standards and regulatory requirements. The EIR enables Indoco Remedies to supply APIs from this facility to the US market, enhancing its global manufacturing credentials and regulatory standing. Indoco Remedies is a fully integrated pharmaceutical company with a turnover of USD 180 million, employing over 6,000 people including 400 scientists and field staff.



Indoco Remedies has achieved a significant regulatory milestone with the receipt of an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) manufacturing facility in Patalganga. The company announced this development through a regulatory filing, following a successful USFDA inspection.

## Regulatory Milestone Details

The EIR from USFDA represents successful completion of the regulatory inspection process for the Patalganga facility. This approval confirms that the manufacturing plant meets the stringent quality standards and regulatory requirements mandated by the US health authority.

Parameter	Details
Facility Type	API Manufacturing Plant
Location	Patalganga
Regulatory Authority	USFDA
Approval Type	Establishment Inspection Report (EIR)

## Strategic Significance

The USFDA EIR approval enhances Indoco Remedies' manufacturing credentials and regulatory standing in the international pharmaceutical market. This certification enables the company to supply APIs manufactured at the Patalganga facility to customers in the United States, one of the world's largest and most lucrative pharmaceutical markets.

The approval demonstrates the company's commitment to maintaining high-quality manufacturing standards and regulatory compliance across its operations. For pharmaceutical companies, USFDA approvals are crucial for accessing the US market and establishing credibility with international customers.

## Company Profile

Indoco Remedies is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The company operates with a turnover of USD 180.00 million and employs over 6,000 people, including more than 400 skilled scientists and field staff.

Company Metrics	Details
Annual Turnover	USD 180.00 million
Employee Strength	Over 6,000
Manufacturing Facilities	11 total (7 for FDFs, 4 for APIs)
Annual Prescriptions	Over 106 million
Doctor Network	Over 240,000 across specialties

This regulatory achievement positions Indoco Remedies favorably for potential business expansion in the US pharmaceutical market and strengthens the company's competitive position in the global API manufacturing sector.

## Historical Stock Returns for Indoco Remedies

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.03%	+2.23%	-5.85%	-13.65%	-28.10%	-10.34%